Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

MorphoSys Rises on $818 Million Drug Alliance: Frankfurt Mover

Don't Miss Out —
Follow us on:

June 27 (Bloomberg) -- MorphoSys AG rose to a 12-year high after announcing an alliance for an experimental cancer treatment with Celgene Corp. worth as much as 628 million euros ($818 million) plus royalties on sales.

The stock jumped 17 percent to 43.50 euros as of 9:42 a.m. in Frankfurt, the highest price since February 2001. That gave the Martinsried, Germany-based company a value of about 1 billion euros. The shares have gained 48 percent this year.

The companies said they will co-develop and co-promote MorphoSys’s MOR202 drug for diseases including multiple myeloma, a type of blood cancer. The deal comes with an upfront payment of 70.8 million euros, and MorphoSys will also receive 46.2 million euros from Summit, New Jersey-based Celgene for new shares of MorphoSys. The German drugmaker is also entitled to payments upon meeting development, regulatory and sales goals as well as a double-digit cut of sales.

“This alliance takes MorphoSys to the next stage of our corporate development,” Chief Executive Officer Simon Moroney said in the statement.

This is MorphoSys’s second transaction this month. The company said June 3 it agreed to sell rights to its experimental MOR103 treatment to GlaxoSmithKline Plc for as much as 445 million euros as well as royalties.

MorphoSys spokeswoman Claudia Gutjahr-Loeser said the company will adjust its financial guidance after it receives U.S. antitrust clearance for the deal. The company raised its forecast for earnings before interest and tax after the GlaxoSmithKline agreement to a range from a loss of 2 million euros to earnings of 2 million euros.

Previously the forecast was for a loss at that level of 18 million euros to 22 million euros.

To contact the reporter on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.